Exact Mass: 331.091

Exact Mass Matches: 331.091

Found 67 metabolites which its exact mass value is equals to given mass value 331.091, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

malvidin

3 4 5 7-tetrahydroxy-3 5-dimethoxyflavylium chloride

[C17H15O7]+ (331.0818)


   

5'-O-Desmethyl omeprazole

2-[(4-Methoxy-3,5-dimethylpyridin-2-yl)methanesulphinyl]-1H-1,3-benzodiazol-6-ol

C16H17N3O3S (331.0991)


5-O-Desmethyl omeprazole is only found in individuals that have used or taken Omeprazole. 5-O-Desmethyl omeprazole is a metabolite of Omeprazole. 5-o-desmethyl omeprazole belongs to the family of Sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.

   

7-Chloro-N-[3-(2-nitroimidazol-1-yl)propyl]quinolin-4-amine

7-chloro-N-[3-(2-nitro-1H-imidazol-1-yl)propyl]quinolin-4-amine

C15H14ClN5O2 (331.0836)


   

(R)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

2-amino-3-(benzylsulfanyl)-N-(4-nitrophenyl)propanamide

C16H17N3O3S (331.0991)


   

Didesethylflurazepam

1-(2-aminoethyl)-7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

C17H15ClFN3O (331.0888)


   

Ggstop

2-Amino-4-((3-(carboxymethyl)phenyl)(methyl)phosphono)butanoic acid

C13H18NO7P (331.0821)


   
   

Europinidin

3,7,3,4-Tetrahydroxy-5,5-dimethoxyflavylium

C17H15O7 (331.0818)


   
   

O1-[(3,5-Dimethylisoxazol-4-yl)carbonyl]-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanehydroximamide

O1-[(3,5-Dimethylisoxazol-4-yl)carbonyl]-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanehydroximamide

C12H12F3N5O3 (331.0892)


   
   
   
   
   
   

Euxylophoricine C

Euxylophoricine C

C19H13N3O3 (331.0957)


   
   

Isofenphos-methyl

Isofenphos-methyl

C14H22NO4PS (331.1007)


   

Z-Phe-chloromethylketone

Z-Phe-chloromethylketone

C18H18ClNO3 (331.0975)


   

MY-5445

1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl-

C20H14ClN3 (331.0876)


MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect[1][2].

   
   

zpck

1-BENZYLOXYCARBONYLAMINOPHENETHYL CHLOROMETHYL KETONE

C18H18ClNO3 (331.0975)


   

5-O-Desmethyl omeprazole

2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazol-6-ol

C16H17N3O3S (331.0991)


   

malvidin

malvidin

C17H15O7+ (331.0818)


An anthocyanidin cation that is delphinidin carrying methyl substituents at positions 3 and 5.

   

7-chloro-4-(4-methylpiperazin-1-yl)-10H-thieno[3,2-c][1]benzazepine

7-chloro-4-(4-methylpiperazin-1-yl)-10H-thieno[3,2-c][1]benzazepine

C17H18ClN3S (331.091)


   

CBZ-S-Phenyl-L-Cysteine

CBZ-S-Phenyl-L-Cysteine

C17H17NO4S (331.0878)


   

4-chlorophenyl-2-acetamido-2-deoxy-beta-d-glucopyranoside

4-chlorophenyl-2-acetamido-2-deoxy-beta-d-glucopyranoside

C14H18ClNO6 (331.0823)


   

4-[2-[[(4-Methylphenyl)sulfonyl]oxy]ethyl]-1,3-dihydro-2H-indole-2-one

4-[2-[[(4-Methylphenyl)sulfonyl]oxy]ethyl]-1,3-dihydro-2H-indole-2-one

C17H17NO4S (331.0878)


   

4-(ISOCYANO(TOSYL)METHYL)-1,2-DIMETHOXYBENZENE

4-(ISOCYANO(TOSYL)METHYL)-1,2-DIMETHOXYBENZENE

C17H17NO4S (331.0878)


   

4-Hydroxy Omeprazole

4-Hydroxy Omeprazole

C16H17N3O3S (331.0991)


   

2-(2-FLUOROACETAMIDO)-5-NITRO-N-(O-TOLYL)BENZAMIDE

2-(2-FLUOROACETAMIDO)-5-NITRO-N-(O-TOLYL)BENZAMIDE

C16H14FN3O4 (331.0968)


   

1-amino-4-hydroxy-2-phenoxyanthraquinone

1-amino-4-hydroxy-2-phenoxyanthraquinone

C20H13NO4 (331.0845)


   

norfluoxetine hydrochloride

norfluoxetine hydrochloride

C16H17ClF3NO (331.0951)


Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity[1][2][3][4].

   

1-Benzyl-7-phenyl-1H-pyrimido[4,5-d][1,3]oxazine-2,4-dione

1-Benzyl-7-phenyl-1H-pyrimido[4,5-d][1,3]oxazine-2,4-dione

C19H13N3O3 (331.0957)


   

tert-butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate

tert-butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate

C14H19Cl2N3O2 (331.0854)


   

Warfarin sodium

Warfarin sodium

C19H16NaO4 (331.0946)


   

(+-)-Benzyloxycarbonyl-alpha-phosphonoglycinetrimethylester

(+-)-Benzyloxycarbonyl-alpha-phosphonoglycinetrimethylester

C13H18NO7P (331.0821)


   

2-METHYL-5-PHENYL-3-(3-SULFOPROPYL)BENZOXAZOLIUM HYDROXIDE, INNER SALT

2-METHYL-5-PHENYL-3-(3-SULFOPROPYL)BENZOXAZOLIUM HYDROXIDE, INNER SALT

C17H17NO4S (331.0878)


   

4-{5-[(2-Chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride (1:1)

4-{5-[(2-Chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride (1:1)

C14H19Cl2N3O2 (331.0854)


   

S-BENZYL-L-CYSTEINE-4-NITROANILINE

(R)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

C16H17N3O3S (331.0991)


   

(Z)-N-[(5-Chloro-2-hydroxyphenyl)(phenyl)methylene]-L-valine

(Z)-N-[(5-Chloro-2-hydroxyphenyl)(phenyl)methylene]-L-valine

C18H18ClNO3 (331.0975)


   

disperse red 60

disperse red 60

C20H13NO4 (331.0845)


   

(R)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE HYDROCHLORIDE

(R)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE HYDROCHLORIDE

C16H17ClF3NO (331.0951)


   

Solvent Red 146

Solvent Red 146

C20H13NO4 (331.0845)


   

(S)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

(S)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

C16H17N3O3S (331.0991)


   

N-[[2-(1-pyrrolidinyl)anilino]-sulfanylidenemethyl]-2-thiophenecarboxamide

N-[[2-(1-pyrrolidinyl)anilino]-sulfanylidenemethyl]-2-thiophenecarboxamide

C16H17N3OS2 (331.0813)


   

Carbamimidothioic acid 2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl ester

Carbamimidothioic acid 2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl ester

C16H17N3O3S (331.0991)


   

4-amino-6,7-diphenyl-2(1H)-pteridinethione

4-amino-6,7-diphenyl-2(1H)-pteridinethione

C18H13N5S (331.0892)


   

3-phenyl-4-[[4-(trifluoromethyl)anilino]methylidene]-1H-pyrazol-5-one

3-phenyl-4-[[4-(trifluoromethyl)anilino]methylidene]-1H-pyrazol-5-one

C17H12F3N3O (331.0932)


   

2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid

2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid

C17H17NO4S (331.0878)


   

Sulochrin(1-)

Sulochrin(1-)

C17H15O7- (331.0818)


A phenolate anion that is the conjugate base of sulochrin, obtained by deprotonation of one of the phenolic hydroxy groups; major species at pH 7.3.

   

5-(3-chlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide

5-(3-chlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide

C15H14ClN5O2 (331.0836)


   

N-{4-[N-(phenylsulfonyl)ethanehydrazonoyl]phenyl}acetamide

N-{4-[N-(phenylsulfonyl)ethanehydrazonoyl]phenyl}acetamide

C16H17N3O3S (331.0991)


   

4-[5-(3-Hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile

4-[5-(3-Hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile

C19H13N3O3 (331.0957)


   

2-[[(4-Tert-butylphenyl)-oxomethyl]amino]-4-chlorobenzoic acid

2-[[(4-Tert-butylphenyl)-oxomethyl]amino]-4-chlorobenzoic acid

C18H18ClNO3 (331.0975)


   

6-{Hydroxy[(4-nitrobenzyl)oxy]phosphoryl}hexanoic acid

6-{Hydroxy[(4-nitrobenzyl)oxy]phosphoryl}hexanoic acid

C13H18NO7P (331.0821)


   

4-[(5Z)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]butanoic acid

4-[(5Z)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]butanoic acid

C17H17NO4S (331.0878)


   

Didesethylflurazepam

Didesethylflurazepam

C17H15ClFN3O (331.0888)


A primary amino compound resulting from the dealkylation of both ethyl groups of the anti-insomnia drug flurazepam. It is the major metabolite of flurazepam.

   

5-O-Desmethyl Omeprazole

5-O-Desmethyl Omeprazole

C16H17N3O3S (331.0991)


   

GAC0001E5

GAC0001E5

C17H12F3N3O (331.0932)


GAC0001E5 is an LXR inverse agonist. GAC0001E5 has antiproliferative activity and can be used in cancer research[1].

   

SW157765

SW157765

C19H13N3O3 (331.0957)


SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs[1][2].

   

(3as)-6-hydroxy-1-(1h-indol-3-yl)-3ah,4h-naphtho[2,1-b]furan-2,5-dione

(3as)-6-hydroxy-1-(1h-indol-3-yl)-3ah,4h-naphtho[2,1-b]furan-2,5-dione

C20H13NO4 (331.0845)


   

4-[(6-hydroxyphenazin-1-yl)amino]benzoic acid

4-[(6-hydroxyphenazin-1-yl)amino]benzoic acid

C19H13N3O3 (331.0957)


   

7-[(4-hydroxy-3-nitrophenyl)methyl]-1,3-dimethylpurine-2,6-dione

7-[(4-hydroxy-3-nitrophenyl)methyl]-1,3-dimethylpurine-2,6-dione

C14H13N5O5 (331.0917)


   

18,20-dioxa-3,13,24-triazahexacyclo[11.11.0.0²,¹⁰.0⁴,⁹.0¹⁵,²³.0¹⁷,²¹]tetracosa-1(24),2(10),4,6,8,15,17(21),22-octaen-14-one

18,20-dioxa-3,13,24-triazahexacyclo[11.11.0.0²,¹⁰.0⁴,⁹.0¹⁵,²³.0¹⁷,²¹]tetracosa-1(24),2(10),4,6,8,15,17(21),22-octaen-14-one

C19H13N3O3 (331.0957)


   

6-hydroxy-5,10-dimethyl-5,10,19-triazapentacyclo[10.7.1.0²,⁷.0⁹,²⁰.0¹³,¹⁸]icosa-1,3,6,9(20),12,14,16,18-octaene-8,11-dione

6-hydroxy-5,10-dimethyl-5,10,19-triazapentacyclo[10.7.1.0²,⁷.0⁹,²⁰.0¹³,¹⁸]icosa-1,3,6,9(20),12,14,16,18-octaene-8,11-dione

C19H13N3O3 (331.0957)


   

6-hydroxy-1-(1h-indol-3-yl)-3ah,4h-naphtho[2,1-b]furan-2,5-dione

6-hydroxy-1-(1h-indol-3-yl)-3ah,4h-naphtho[2,1-b]furan-2,5-dione

C20H13NO4 (331.0845)